Joby Aviation posted a solid Q3 2026 with revenue of $55.09 million and a per-share loss of $0.22, beating estimates and lifting the full-year revenue outlook to $135–$140 million. Management highlighted progress toward FAA certification, expanded autonomy-focused U.S. Air Force contracts near $37 million, and a potential autonomous flight milestone for the J208. While the cash burn guidance remains a key risk, these catalysts suggest upside potential in the near term.
ARK Invest's large purchase signals renewed institutional interest ahead of Joby's November 4 Q3 print. The stock has momentum from ARK's bets, but remains structurally weak with a long-term gap to major moving averages. If Q3 beats and guidance holds, near-term upside to test $5–$6 could unfold before fading risk persists.
Joby Aviation reported a 3,100-mile cross-country autonomous flight with no pilot intervention, remotely supervised from California and Shaw AFB. The test validates its autonomy stack across environments and hints at broader applications in medical, disaster, and defense logistics, beyond eVTOL urban air taxis. Near-term upside hinges on FAA certification progress and potential defense program momentum.
Joby kicked off real-world flight demonstrations in Texas under the federal eVTOL Integration Pilot Program while the J208 autonomous plane tours coast-to-coast. Texas leasing a 45,000-square-foot facility signals a longer-term footprint, and the cross-country autonomy effort highlights potential revenue uses. In the near term, the stock remains under pressure despite regulatory-data progress.
Joby reported second-quarter results and announced a new Texas facility to support its upcoming eVTOL flight program. The combination signals progress on testing and scaling capabilities, potentially reducing timelines toward certification and commercial rollout. Traders will await detailed cash flow numbers and guidance to gauge runway for capital needs and margin trajectory.
Joby Aviation announced a roughly $500 million acquisition of Resonant Sciences to bolster its defense-market ambitions. The deal signals a strategic shift from civil eVTOL toward defense tech, potentially expanding revenue and contracts if integration proceeds smoothly. Financing structure and integration risk remain key near-term uncertainties for margin and cash flow.